key: cord-0713658-imwppqcy authors: Pillaiyar, Thanigaimalai; Laufer, Stefan title: Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy date: 2021-06-03 journal: J Med Chem DOI: 10.1021/acs.jmedchem.1c00335 sha: 5b70b66f3d6f98bfc160b112d12262c5a2117239 doc_id: 713658 cord_uid: imwppqcy [Image: see text] The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as an etiological agent for COVID-19. Several kinases have been proposed as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, Middle East syndrome coronavirus (MERS-CoV), and SARS-CoV-2. Viral infections hijack abundant cell signaling pathways, resulting in drastic phosphorylation rewiring in the host and viral proteins. Some kinases play a significant role throughout the viral infection cycle (entry, replication, assembly, and egress), and several of them are involved in the virus-induced hyperinflammatory response that leads to cytokine storm, acute respiratory distress syndrome (ARDS), organ injury, and death. Here, we highlight kinases that are associated with coronavirus infections and their inhibitors with antiviral and potentially anti-inflammatory, cytokine-suppressive, or antifibrotic activity. The coronavirus disease-19 (COVID-19) pandemic is a potentially fatal respiratory infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1,2 SARS-CoV-2 first appeared in previously unexposed human populations in late 2019 in Wuhan, China, from an undisclosed source. Subsequently, the virus rapidly spread worldwide with a high transmission efficacy. 3, 4 According to the latest data, as of April 20, 2021, the virus has affected more than 140 million people, and deaths have surpassed more than 3 million. 5 The unprecedented efforts from health care workers, industry, and academic scientists have resulted in a wide variety of vaccines, several of which have recently been authorized and recommended for use in controlling the SARS-CoV-2 spread around the world. The U.S. Food and Drug Administration (FDA) approved remdesivir in October for use in adult and pediatric patients aged 12 and up with COVID-19 who need hospitalization. However, the World Health Organization (WHO) has not recommended the use of remdesivir irrespective of the seriousness of the disorder, as there is no evidence that it improves survival and other outcomes in hospitalized patients. Moreover, the WHO recommends that seriously ill COVID-19 patients receive systemic corticosteroid medication (e.g., 6 mg dexamethasone daily) for 7−10 days but that nonsevere COVID-19 patients should not receive this treatment. Antibodies like bamlanivimab and etesevimab, which have been approved by the FDA, are only for emergency use in patients with mild to severe COVID-19. However, they were not approved for patients who are hospitalized or need oxygen therapy due to COVID-19. 6 Monoclonal antibodies can be associated with poorer outcomes in hospitalized COVID-19 patients who require oxygen or mechanical ventilation. As a result, treatment options for human coronavirus (HCoV) diseases are limited, and experts expect that the virus will survive for a longer period. It is essential to comprehend the coronavirus's basic features and life cycle to develop potential antiviral therapeutics. Coronaviruses are enveloped, positive-sense RNA viruses with the world's largest viral RNA genome (∼26−32 kilobases) 7 that comprises about 30 000 nucleotides. So far, seven human coronaviruses have been discovered, and they are classified into four main genera (α, β, γ, and δ) under the family Coronaviridae: 8 α-CoVs are (i) HCoV-229E and (ii) HCoV-OC43, and β-CoVs are (iii) HCoV-HKU1, (iv) HCoV-NL63, (v) SARS-CoV-1, (vi) MERS-CoV, and (vii) SARS-CoV-2 ( Figure 1 ). 9, 10 Of the three last-mentioned β-coronaviruses, inflammatory immune response contributes to ARDS, respiratory failure, organ failure affecting the heart, liver, kidney, and central nervous system (CNS), 26 and death from severe infection. 3 Of all the host resources, cellular kinases can play a part in various stages of the virus's life cycle. Numerous kinases have been suggested as potential mediators of different virus infections. Several kinases have been suggested as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, MERS-CoV, and SARS-CoV-2 (Table 1) . 27 SARS-CoV-1 and MERS-CoV fusion with the endosomal membrane is mediated by Abelson (Abl) kinases. 28, 29 For the replication of the murine coronavirus HCoV-229E and other unrelated viruses, activation of p38 MAPK and c-Jun N terminal kinases (JNK1/2) is needed. 30−32 Studies revealed that p38 is implicated in the phosphorylation of the initial translation factor eIF4E, which plays a crucial role in the translation of viral mRNAs and subsequent production of infection of murine CoV (mCoV). 31 The p38 MAPK/ERK signaling pathway has been employed in the entry and production of the influenza A and Ebola viruses. 33 36 protein kinase II, 37 ERK1/2/5, 27 EGFR, 27 GSK-3, 38 JAK/STAT, 27 p38 MAPK, 27 NAK, SFK signaling pathway, 27 PI3K/Akt, mTOR, 27 AXL, 39 CDK, 39 CK2, 39 Abl kinases 40 viral life cycle (entry, replication, assembly, release), hyperimmune activation, proinflammatory cytokine production, cell cycle regulation (pneumonia, inflammation, and fibrosis) Abl kinases, 41, 42 p38 MAPK, ERK1/2/5, PI3K/Akt/mTOR, 43 SFK signaling pathway 44 viral life cycle (entry, replication), symptom associated diseases HCoV-229E p38 MAPK, 32 SFK signaling pathway 44 HCoV-OC43 receptor-interacting protein kinase 1, 45 mixed lineage kinase domain-like 45 Many kinases also play a role in the progression of symptoms like pneumonia, inflammation, and fibrosis that are linked to CoV infections. 27, 39, 46 Kinases respond to and regulate the synthesis of potentially harmful cytokines (IL-6, IL-10, and TNF) and proteins associated with inflammation and pulmonary fibrosis induction (such as the proinflammatory cytokine TGF-β). 47, 48 Therefore, kinase inhibitors can have direct antiviral effects and anti-inflammatory, cytokine-suppressive, and antifibrotic activities, all of which may be useful in the fight against respiratory viral infections ( Figure 3 ). Indeed, several kinase inhibitors are currently being tested in clinical trials for COVID-19 therapy. Several reviews have been published that illustrate the function of cellular kinases in a variety of viral infections. Raghuvanshi and Bharate discussed how kinase inhibitors have recently been developed to treat various viral infections. 49 They primarily focused on different stages of kinase inhibitors as FDA approved, clinical candidates and on discovery that targeted various virus infections, but they did not discuss kinase inhibitors that target human coronaviruses to date. Several research groups reviewed the critical function of different host kinases in influenza A virus infection. 50−52 Schor and Einav discussed the possibility of repurposing branded kinase inhibitors to have broad antiviral efficacy. 53 Weisberg et al. focused solely on repurposing licensed kinase inhibitors against SARS-CoV-2, the new COVID-19 pandemic's causative agent. 27 However, no systematic review of kinase inhibitors as anticoronaviral agents has been published to date. In this Perspective, we systematically discuss different kinases associated with coronavirus infections and their inhibitors with antiviral and potential for anti-inflammatory, cytokine-suppressive, or antifibrotic activity. 56 and vaccinia virus. 57 Abl kinases, which are involved in viral entry and replication, have recently been identified as possible therapeutic targets for coronavirus diseases. Dyall et al. screened approved or experimental drug libraries to identify potential therapeutics against SARS-CoV-1 and MERS-CoV. 58 This led to the development of three kinase signaling pathway inhibitors: imatinib, dasatinib, and nilotinib. Imatinib and dasatinib were active against SARS-CoV-1 and MERS-CoV, while nilotinib was only active against SARS-CoV-1 ( Figure 4 ). Both imatinib (4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]-amino}phenyl)benzamide) and dasatinib (N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate) inhibit SARS-CoV-1 and MERS-CoV with EC 50 values of 2.1− 17.6 μM, though SARS-CoV-1 appeared to be sensitive to these kinase inhibitors as well. Dasatinib, for example, inhibited SARS-CoV-1 with a low micromolar EC 50 of 2.1 μM, while the EC 50 for inhibiting MERS-CoV was 5.4 μM. Imatinib, instead, needed a high concentration (EC 50 9.23 μM) to inhibit SARS-CoV-1, despite having been confirmed to inhibit the Ebola virus, coxsackievirus B, and vaccinia virus with concentrations in the same range. 4, 58 Imatinib is an orally available Abl kinase inhibitor for chronic myeloid leukemia (CML) treatment. 59 Dasatinib is an orally available, second generation Abl kinase inhibitor for CML and acute lymphoblastic leukemia (ALL). 60 Nilotinib (4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide), a structural analogy to imatinib, has been used to treat CML. It inhibited the SARS-CoV-1 replication in the micromolar range without compromising cell cytotoxicity but not significantly inhibiting the MERS-CoV (only 39% inhibition). In Abl-expressing cells, nilotinib, rather than imatinib, effectively blocked Abl activity and proliferation. 41,60−63 In the subsequent study, imatinib was discovered to be effective in preventing viral infection in its early stages for SARS-CoV-1 and MERS-CoV. 28 It blocked viral entry and replication by preventing virions from fusing at the endosomal membrane. Further insights into mechanistic studies revealed the SARS-CoV-1 and MERS-CoV to rely on Abl2 kinase activity for viral entry but not on Abl1 kinase: inhibition of Abl2 kinase by imatinib blocks viral entry. Imatinib was previously found to inhibit the Ebola virus, poxvirus, and coxsackievirus. 40, 54, 56 SH2 and SH3 domains in Abl2 kinase hold the protein in a dormant state. 64 Since the substrate binds to either the SH2 or the SH3 domain, Abl2 may turn from its inactive to active state. 42 Adenosine triphosphate (ATP) binding at the catalytic site and corresponding kinase activity are allowed by Abl2's open, active conformation. It has been proposed that coronavirus infection increases Abl2 substrate binding, allowing Abl2 into an active state and phosphorylate downstream targets. 65 Imatinib inhibited the kinases activity of Abl2 by preventing the phosphorylation of proteins in cells. Since SARS-CoV-1 and SARS-CoV-2 have a high degree of genome sequence identity (80%), imatinib is predicted to inhibit SARS-CoV-2 as well. Zhao et al. utilized pseudotyped viruses with SARS-CoV-2 spike protein to study imatinib's anti-SARS-CoV-2 activity in Caco-2 cells. 66 At concentrations up to 10 μM, imatinib, on the other hand, did not affect SARS-CoV-2 entry or infection. This result supports the weak activity of imatinib in inhibiting SARS-CoV-1 replication in Vero cells (EC 50 9.85 μM). 58 Severe COVID-19 is characterized by ARDS triggered by enhanced proinflammatory cytokine production. Imatinib has immunomodulatory effects 66, 68 and inhibits cytokine receptor signaling (PDGFR, c-Kit, and CSF1R), potentially suppressing cytokine storms. As a result of its immunomodulatory effects, imatinib may display clinical benefits for COVID-19. In contrast to Zhao et al., a recent preprint reported imatinib to effectively inhibit SARS-CoV-2 replication with an IC 50 value of 130 nM. 69 However, it was toxic in concentrations between 25 and 3.2 μM. For both SARS-CoV-1 and MERS-CoV virus fusion inhibition, imatinib's antiviral efficacy was the same. Furthermore, imatinib binds to the SARS-CoV-2 spike protein's receptor-binding domain (RBD) with a 2.32 μM affinity, meaning that imatinib did not specifically inhibit the SARS-CoV-2 RBD/ACE2 interaction. As a result, imatinib inhibited both cellular tyrosine kinase and viral fusion, preventing virus replication. Indeed, three clinical trials investigating the therapeutic efficacy of imatinib in COVID-19 patients are currently underway: NCT04394416 (USA), EudraCT2020-001236-10 (The Netherlands), and NCT04357613 (France). Galimberti et al. reported tyrosine kinase inhibitors (TKIs) to play a protective role against SARS-CoV-2 in patients with Ph+ ALL and CML. 46 In Ph+ ALL and CML Italian cohorts, they found just a few cases of COVID-19. According to the evidence, the use of TKIs may be to account for the low infection rate. It was interesting to see that during treatment of patients with TKIs, such as imatinib or nilotinib, several "proimmune" genes such as CD28 and IFN γ were induced, whereas the expression of anti-immune genes such as ARG-1, CEACAM1, and FUT4 was reduced. The entry of the virus, which includes receptor binding, S glycoprotein modification, and proteolysis, is the first step in viral replication. Cathepsin L and the transmembrane serine protease 2 (TTSP) TMPRSS2 are playing crucial roles in viral entry. Cathepsin L mediates the proteolysis, 70 while TMPRSS2 helps in the CoV S glycoprotein cleavage to enter the host cells. 71 It was discovered that inhibiting cathepsin L prevented SARS-CoV-1 infection and that using a mixture of EST (a cathepsin inhibitor) and camostat (a serine protease inhibitor, Figure 4 ) prevented viral entry and replication completely. The study indicated that imatinib inhibits the functionality or action of TMPRSS2. 28 On the other hand, Abl and ARG kinases have been linked to promoting the production of the endosomal protease cathepsin L in cancer cells. 72 Thus, inhibiting cathepsin L in the context of viral replication by targeting these kinases may be a promising strategy. (Figure 4 ) inhibited the assembly of the dengue virus. 76 The antiviral activity of these agents contributed to inhibiting SFKs, especially c-Src and Fyn. Saracatinib is a Phase III investigational dual kinase inhibitor that inhibits both Src and Bcr-Abl tyrosine kinases. Shin et al. discovered that saracatinib inhibited MERS-CoV in Huh-7 cells at an early stage of its life cycle (EC 50 of 2.9 M, CC 50 of >50 μM). 44 The authors hypothesized that saracatinib could inhibit MERS-CoV by inhibiting SFK signaling pathways. In a subsequent study, they identified the targets of saracatinib as Lyn and Fyn through a siRNA knock-down study. The study also showed that knocking out Lyn and Fyn resulted in a substantial reduction in viral load, implying that these kinases are needed for effective MERS-CoV replication. In Huh-7 cells, however, knockdown of Yes had little effect on MERS-CoV replication. The coadministration of saracatinib with gemcitabine ( Figure 4 ), a chemotherapy medication for different types of cancers, showed a synergistic effect. Saracatinib also demonstrated broad antiviral activity against HCoV-229E and HCoV-OC43, with EC 50 values of 2.4 and 5.1 μM, respectively. 44 Src family kinases have also been shown to be potential molecular targets for HCV77 and dengue virus infection and replication. Kumar et al. discovered that the Src kinase (Csk) is a critical host kinase in dengue virus replication. 75 Dengue virus RNA levels were suppressed when Csk expression was knocked down by siRNA or inhibitor, and dengue infection was greatly reduced when cells lacked Src kinases (Fyn, Src, and Yes). This data indicates that Src kinases are crucial players in dengue virus replication and assembly. Csk was identified to be hyperphosphorylated during virus infection, and inhibiting protein kinase A (PKA) prevented viral replication, implying that PKA phosphorylation of Csk is involved in the dengue virus life cycle. Chu 74 Mechanistic studies demonstrated that dasatinib prevents the formation of infectious virus particles. Saracatinib and dasatinib were identified as effective agents against the dengue virus, and both of them targeted Fyn for RNA replication. 76 The genetic knock-down study of Yes was shown to inhibit the West Nile virus titer through the virus replication cycle. 78 3.3. Numb-Associated Kinase (NAK) Family and AXL Kinase Inhibitors. The numb-associated family of Ser/Ther kinases plays a crucial role in the replication of many unrelated viruses. 26 Four human homologues are in the family: (i) AK1 adaptor protein-associated kinase 1 (AAK1), (ii) BMP-2inducible kinase (BIKE/BMP2K), (iii) cyclin G-associated kinase (GAK), and (iv) myristoylated and palmitoylated serine/ threonine kinase 1 (MPSK1). Two of these homologues, AAK1 and GAK, have been linked to the entry, assembly, and release of viruses such as dengue, HCV, Ebola, SARS-CoV-1 and -2, and MERS-CoV. 79−86 Sunitinib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) and erlotinib (N-(3-ethynylphenyl)-6,7-bis(2methoxyethoxy)quinazolin-4-amine) (for structures, see Figure 5 ) potentially suppressed AAK1 and GAK and showed antiviral action against dengue and ebolaviruses in cultured cells. 78, 87 The gene silencing of AAK1 and GAK demonstrated their crucial role in viral entry and infection. 83 Sunitinib and erlotinib were found to prevent viral infection through inhibiting AP-mediated intracellular membrane trafficking by AAK1 and GAK at the molecular level. 87 In murine models of dengue and ebolaviruses, the drug combination sunitinib/erlotinib has been shown to minimize morbidity and mortality. 7 However, the dosage required for inhibiting AAK1 and GAK by sunitinib and erlotinib would be much higher in COVID-19 patients. 86 Sunitinib is an approved multitargeted kinase inhibitor used for renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) treatment. Erlotinib is an EGFR tyrosine kinase inhibitor, which has been licensed by the FDA for the treatment of metastatic non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib is one of the World Health Organization's Essential Medicines. Baricitinib (2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile) has re-cently been suggested as a promising inhibitor of SARS-CoV-2 activity ( Figure 5 ). 86 Indeed, baricitinib showed a promising result for ARDS in COVID-19. In November 2020, the FDA approved baricitinib for emergency use authorization (EUA) status for COVID-19 care in hospitalized patients in combination with remdesivir. 88 Baricitinib is an inhibitor of Janus kinase-1 (JAK-1) and JAK-2, and it has been licensed for treating rheumatoid arthritis and myelofibrosis. 86 ACE2 has several regulators, among which AAK1 and Gassociated kinase (GAK) are known for clathrin-mediated endocytosis. The mode of action of baricitinib on viral entry and controlling ARDS are indicated in Figure 6 . Baricitinib not only reduced the ARDS in patients but also interrupted the passage and intracellular assembly of SARS-CoV-2 into the target cells by inhibiting the AAK1 signaling. Furthermore, the clinical dose of baricitinib (2 or 4 mg once daily) rendered it superior as an antiviral agent. In vitro studies demonstrated baricitinib's antiviral properties, and therapy with baricitinib boosted the clinical results of COVID-19 patients. Baricitinib reduced the SARS-CoV-2 viral load by 30−40% in primary human liver spheroids at 400 and 500 nM concentrations, indicating antiviral activity. 89 In human clinical trials with effectiveness in rheumatoid arthritis (RA) patients, baricitinib had a high oral bioavailability (79%) and was well tolerated. 90 Furthermore, baricitinib is a unique candidate for the treatment of COVID-19 because of its favorable side-effect profile, low plasma protein binding, and negligible involvement with CYP enzymes. Baricitinib's possible role in the treatment of COVID-19 patients has recently been highlighted. The study examined the safety and effectiveness of baricitinib in COVID-19 patients and found that it provided substantial clinical improvement with no infections or side effects 2 weeks after treatment. These findings indicated that using baricitinib for a brief period (1−2 weeks) was the best way to mitigate viral replication and an abnormal host inflammatory response when on the therapeutic dosage. Another study demonstrated baricitinib as a potential drug to reduce systematic inflammation caused by SARS-CoV-2 infection in rhesus macaques. 92 Inflammation was minimized in animals given baricitinib. More specifically, baricitinib-treated animals had a rapid and potent inhibition of inflammationrelated cytokines and chemokines. These data indicated the beneficial role of baricitinib as a potential candidate for the management of inflammation induced by SARS-CoV-2 infection. The antiviral effect of baricitinib is being studied in several clinical trials either alone or combined with other antivirals for COVID-19 (https://clinicaltrials.gov/ct2/results?cond= Baricitinib) (see Table 2 ). The anti-SARS-CoV actions of baricitinib in conjunction with remdesivir are being studied in the Adaptive COVID-19 Treatment Trial (ACTT-2; NCT04401579). The FDA approved this combination in November 2020 for emergency use in hospitalized COVID/ 19 patients who need oxygen. 93 Baricitinib is being studied as a monotherapy in the COV-BARRIER trial (NCT04421027). Also, baricitinib is proposed to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by the ACE2 receptor. 94 3.4. AXL Kinase Inhibitors. AXL, a tyrosine kinase on the cell surface, controls cell replication, growth, differentiation, and immunity. 95−98 Upon activation by its ligands such as vitamin-K-dependent protein growth-arrest-specific gene 6 (GAS 6), AXL stimulates various downstream signaling pathways that 103 AXL has been confirmed to serve as a viral entry factor/immune modulator. AXL a has crucial role in the relationship between the virus and the host. AXL facilitated virus entry and modulated the antiviral state of human Sertoli cells during Zika virus infection. 7 AXL inhibition led to decreased suppressor of the cytokine signaling-1 (SOCS1) and SOCS3 proteins, increased expression of IFNγ, and reduced replication. In a recently published study, the authors discovered that AXL interacts with the SARS-CoV-2 S glycoprotein on the host cell membrane, allowing the virus to enter the cell. 104 SARS-CoV-2 virus entry into pulmonary and bronchial epithelial cells was substantially reduced when AXL was knocked down in H1299 and A549 cells, indicating that AXL is needed for SARS-CoV-2 virus entry. Recently, gilteritinib (6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide) ( Figure 5 ) was reported to inhibit the replication of SARS-CoV-2 with an IC 50 value of 0.807 μM in cellular assays. 39 The inhibition of AXL kinase, which is upstream of p38, led to gilteritinib's anti-SARS-CoV-2 replication function. The use of bemcentinib, an AXL inhibitor, in the RECOVERY COVID-19 trial in the United Kingdom, backs up this argument. Gilteritinib is a tyrosine kinase inhibitor105 that has been licensed for the treatment of AML. 3.5. EGFR Signaling Pathway Inhibitors. The epidermal growth factor receptor (EGFR) is a prototypical tyrosine kinase (RTK) receptor. Activation of the EGFR signaling pathway influences a range of cell functions, including cell proliferation, survival, growth, and development. 106 The EGFR signaling pathway has been identified as one of the crucial players in cancer pathogenesis and has also been linked to various viruses, 107−109 such as the spread and mortality of the vaccinia virus and the process of entry for influenza A, HCV, and Epstein−Barr viruses. 110, 111 EGFR is a cofactor for HCV entry into human host cells. Activation of EGFR signaling leads to suppressed interferon signaling in respiratory virus diseases (influenza and rhinovirus). 112 A loss of functional STAT1 has been associated with the upregulation of EGFR, which may indirectly activate STAT3 constitutively. As a result, targeting EGFR as an approach to managing COVID-19 could be a viable option. A synergized antiviral reaction against HCV was observed when a possible EGFR inhibitor, erlotinib, was combined with IFN-1 therapy. The reduction of IFN1-induced STAT3 by enhancing SOCS3 expression was the mode of the action of erlotinib. 111 Osimertinib prop-2-enamide) was reported to be an effective inhibitor of SARS-CoV-2 S protein (EC 50 3.98 μM) (Figure 7) . 113 It rescued 60% of the SARS-CoV-2 cytopathogenic effect (CPE), though cytotoxicity limited the therapeutic window. 113 Osimertinib is an EGFR inhibitor that has been approved for the treatment of NSCLC. 114 Klann et al. recently confirmed that many EGFR inhibitors inhibited the replication of SARS-CoV-2. 115 They used the colon epithelial cell line Caco-2, which is extremely permissive for the virus, to create a SARS-CoV-2-infected in vitro cell culture model. 116, 117 The cellular phosphoprotein networks revealed extensive cellular signaling pathway rearrangements after infection with SARS-CoV-2, especially GFR signaling. Pictilisib (IC 50 2.58 μM), a PI3K inhibitor, and omipalisib (IC 50 0.014 μM), a dual PI3K/mTOR inhibitor, inhibited viral replication in cells 115 EGFR-mediated STAT3 activation is controlled by the RAS/ RAF/MAPK and PI3K pathways, and inhibition of these pathways will potentiate IFN-1 and anti-SARS-CoV-2 activity in a synergistic manner. GFR signaling is also implicated in SARS-CoV-1-induced fibrosis. 107, 109, 115, 116, 124, 125 An inhibitor, omipalisib, has been shown to slow fibrosis development in patients with idiopathic pulmonary fibrosis, which may be related to the deregulation of GFR signaling pathways in coronavirus patients' lung fibrosis. 126 Several unrelated viruses activate the PI3K/Akt/mTOR pathway to enhance their replication. 127 For example, (Figure 7) , an approved mTOR inhibitor, showed moderate inhibitory activity (56 or 59% inhibition at 10 μM) against MERS-CoV based on whether it was added pre-or postinfection. Miltefosine (Figure 7) , an approved Akt inhibitor for leishmanial infection, had minimal (28%) or no activity against MERS-CoV at the highest concentration tested when added preor postinfectionally. 143 Teriflunomide, an active metabolite of leflunomide, on the other hand, demonstrated good anti-HCV activity in both in vitro and in vivo studies. 130 Leflunomide, a drug that inhibits Akt phosphorylation, has been approved for rheumatoid arthritis. AXL is known to control various signaling pathways including PI3K, Ras/ERK, and p38. Therefore, the inhibition of AXL may contribute to the downregulation of p38 signaling. PI3K/Akt/ mTOR activation has been demonstrated in the growth and replication of various unrelated viruses such as HCV, WNV, and influenza A virus. 128, 129 Wortmannin (Figure 7) , a covalent inhibitor of PI3Ks, had a 40% inhibitory effect on MERS-CoV. At a concentration of 10 μM, the mTOR inhibitor rapamycin (Figure 7) inhibited MERS-CoV replication in virus-infected cells by 61%. 43 Rapamycin is a macrolide compound and has an immunosuppressant function in humans. 3.7. Cyclin Dependent Kinases (CDKs) Inhibitors. CDKs are kinases that control the cell cycle and have been targeted for anticancer drugs. CDKs are also used in infectious diseases, where the virus alters the expression and function of host CDKs to influence cell cycle progression. 115 For example, several viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), Zika virus, and herpes simplex virus (HSV) have been linked to CDKs. 131 CDK4 and CD6 have been validated as potential targets for the inhibition of HIV-1 infection, 132, 133 and CDK9 for herpes simplex virus type 1 (HSV-1) infection. 134 An adenovirus promotes progression into the late G1/S process by increasing CDK2 phosphorylation. 135 Figure 8 ), a licensed inhibitor of CDK4/6, was able to inhibit HSV-1, and HSV-1 replication in vitro, possibly through a blockade of cellular protein phosphorylation. 141 SARS-CoV-2 significantly reduced CDK1/2 behaviors during infection, resulting in an S/G2 phase arrest, close to infectious bronchitis virus (IBV), 142, 143 and other RNA viruses, 144, 145 according to a recent report. This indicates that the SARS-CoV-2 virus can control the cell cycle to boost the viral life cycle. 146 Dinaciclib is being tested in clinical studies for different types of variety of cancer. Recently, dinaciclib has shown strong anti-SARS-CoV-2 activity. 39 The antiviral activity of dinaciclib in two cell lines (Vero E6 and A549-ACE2 cells) infected with SARS-CoV-2 showed IC 50 0.127 μM and IC 50 0.032 μM, respectively. 39 The phosphatidylinositol enzyme activities of PIK3CQ, PLCB3, and PIKFYVE were also highlighted in the same study showing that the required balance of phosphatidylinositol species may play a role. The pharmacological inhibition of PIKFYVE, an FYVE fingercontaining phosphoinositide kinase, by its inhibitor apilimod (N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine) (Figure 8 ) exhibited strong anti-SARS-CoV-2 activity in two cell lines (Vero E6, IC 50 < 0.08 μM; A549-ACE2, IC 50 0.007 μM). Apilimod was first discovered as an inhibitor of IL-12 and IL-23, but it was recently repurposed for Ebola and Lassa virus fever. 147−149 Interestingly, abemaciclib (N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine) (Figure 8 ) showed specific inhibition of SARS-CoV-2 S (EC 50 in Calu3 cell lines). 113 The SARS-CoV-2 CPE was reduced by 60% using this compound. 113 Abemaciclib is a selective CDK4/6 inhibitor that has been used for the treatment of metastatic breast cancer. 150, 151 In general, CDK inhibitors block viral genome replication in host cells as part of their antiviral mechanism of action. 1 Abemaciclib, on the other hand, inhibits coronavirus CPE by blocking cell entry, meaning that this compound may be optimized as an active SARS-CoV-2 entry inhibitor. 3.8. Casein Kinase 2 Inhibitors. Casein kinase 2 (CK2/ CSNK2) regulates various cellular processes and is essential for the life cycle of several unrelated viruses such as vesicular stomatitis virus (VCV), HIV, HCV, human papillomavirus (HPV), and HSV-1. 152, 153 Recent shreds of evidence suggest that CK2 is involved in various mechanisms to downregulate the potential of cells to generate IFN-1 in response to viral infection. 154 Thus, the pharmacological intervention of CK2 has been considered a potential strategy for antiviral treatment. CK2 is involved in the development of actin tails during vaccinia infection, which allows the virus to travel efficiently from cell to cell. 155 The inhibition of CK2 by its selective inhibitor TBBz (at 8.0 μM concentration) impaired the vaccinia virus spread and actin tail formation. According to a recent analysis, the SARS-CoV-2 nucleocapsid (N) directly targets CK2, and they both colocalize at the filopodia protrusions, which may be essential for virus egress and rapid cell-to-cell spread. 39 The inhibition of CK2 by silmitasertib The recent clinical trial of intravenous CIGB-325 (formerly known as CIGB-300), a peptidic inhibitor of CK2, in patients with COVID-19 (https://covid-19.cochrane.org/studies/crs-13844822, code: IG/CIGB300I/CV/2001) investigated the function of CK2 in coronavirus infection. 156 Twenty patients were randomly allocated to receive either CIGB-325 (2.5 mg/ kg/day for 5 days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). In COVID-19 patients with pneumonia on day 7 received a mixture of CIGB-325 and standard-of-care enhanced chest computed tomography (CT). This study proposed that inhibiting CK2 could be a good way to treat COVID-19. For the treatment of COVID-19, a significant number of CK2 inhibitors must be investigated. For example, quercetin and enzymatically modified isoquercitrin (EMIQ) have been suggested as potential candidates. 154 4.1. Inhibitors of the p38 MAPK Signaling Pathway. The p38 MAPK signaling pathway is activated by various factors, such as environmental stress, pathogenic infection, and proinflammatory cytokines, and is involved in cell differentiation, apoptosis, and autophagy. Several pathogenic viruses, including SARS-CoV-1, DENV, and IBA activate the p38 MAPK, which results in unregulated inflammatory responses linked to serious diseases. Therefore, the p38 MAPK pathway Figure 9 . CK2 inhibitors for SARS-CoV-2 (silmitasertib: IC 50 1.28 μM), 39 vaccinia virus (4,5,6,7-tetrabromo-1H-benzimidazole (TBBz)), 155 and quercetin. could be used to regulate proinflammatory cytokine production caused by multiple viral infections. 158−160 The reason for death in COVID-19 patients mainly occurs due to the overwhelming inflammatory effect that leads to ARDS and myocarditis. 161 The p38 MAPK pathway has previously been linked to the inflammatory response in animal models of acute lung injury and myocarditis. 162, 163 The p38 MAPK pathway is activated, which enhances the synthesis of cytokines including IL-6, TNF-α, and β. 164 Therefore, it has been proposed that the upregulation of the p38 MAPK pathway may be one of the causes of inflammatory injury in SARS-CoV-2 patients. SARS-CoV-2 uses ACE2 to enter host cells, much as SARS-CoV-1 did. 165 Studies revealed that, following SARS-Co-1 infection, ACE2 expression is reduced in lungs, leading to disruption of the renin-angiotensin system. 166 ACE2 transforms angiotensin II (Ang1−8) to angiotensin I (Ang1−7), which activates the Mas receptor and induces the anti-inflammatory, antiproliferogenic, antifibrogenic, and vasodilation effects by downregulation of p38 MAPK activation ( Figure 10 ). 167 Angiotensin II activation of p38 MAPK, on the other hand, indicates proinflammatory, provasoconstrictive, and prothrombotic action. The p38 MAPK network is complicated, and it interacts with several signaling pathways and proinflammatory cytokines that cause ARDS and organ damage in SARS-CoV-1 and SARS-CoV-2 patients. 168 −170 It has been proposed that the viral entry suppresses the ACE2 activity to produce Ang1−7, leading to an increased expression of inflammatory responses by activating the p38 MAPK pathway in the lungs and heart. Additionally, p38 MAPK activation Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective upregulates ADAM17, reducing the supply of ACE2 activity even further. 171 Therefore, ACE2 inhibitors or ACE blockers that balance the renin-angiotensin system may be useful for COVID-19 management. 157 Indeed, proinflammatory AngII levels were linearly correlated with the degree of lung damage and viral load in a recent study of COVID-19 patients, implying a RAS deficiency in the pathogenesis of COVID-19. 172, 173 Bouhaddou et al. recently investigated whether the p38 MAPK pathway was involved in the formation of cytokines in SARS-CoV-2-infected ACE2-A549 cells that were treated with the p38 inhibitor SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole, Figure 11 ). 39 In a dosedependent way, the inhibitor reduced the mRNA of cytokines such as IL-6, TNF, and others that were elevated during infection. Interestingly, this p38 inhibition led to reducing SARS-CoV-2 replication without significant cellular cytotoxicity. In an ELISA study of supernatant cells, SB203580 inhibited the expression of IL-6, CXCL8, CCL20, and CCL2. An anti-SARS-CoV-2 N protein antibody-based assay confirmed SB203580s inhibitory activity in viral reduction. They also reported that SARS-CoV-2 infection caused cell cycle arrest between the S and G2 phases, implying that p38 activity and cell cycle arrest are systematically related during infection. At a 10 μM concentration, SB203580 prevented MERS-CoV by 45% through p38/MAPK. 32 SB203580 showed antiviral activity against HCoV-229E and, at 4 μM concentration, reduced the viral RNA by ∼60%. 32 In ACE2-A549 cells, the MAPK signaling pathway dependency of SARS-CoV-2 infection was investigated during viral infection. Bouhaddou It has antiviral activity against mCoV in vitro, with an IC 50 of 10 μM. 20(S)Ginsenoside inhibits mCoV by suppressing the p38/ JNK/MAPK signaling pathway. 174 The presence of another small molecule AXL inhibitor, bemcentinib, in the RECOVERY COVID-19 Phase II clinical trial COVID-19 patients backed up gilteritinib's antiviral efficacy. 175 Bemcentinib was previously reported to show potent antiviral activity against Ebola and Zika virus in preclinical studies. 176, 177 Ralimetinib is being tested in Phase II clinical trials for ovarian cancer, 178 and ARRY-797 is being tested in Phase III clinical trials for cardiomyopathy, a degenerative cardiovascular disease. Some previous reports revealed that p38 is directly involved in the replication of respiratory viruses like SARS-CoV-1 and H5N1. 179−181 p38 MAPK signaling induces the receptormediated endocytosis for the viral entry, 182 and its activation is also employed in the endocytosis of ACE2. 183−185 These findings indicated that SARS-CoV-2 may use a related mechanism to activate p38 MAPK directly. Indeed, SARS-CoV-2 triggered p38 MAPK in vitro, according to a recent report. 186 Treatment of SARS-CoV-1 infected mice with a p38 inhibitor resulted in an 80% survival rate in the treatment community relative to the control group in a preclinical trial (0%). 160 When cells detect a viral attack, they activate numerous downstream interferon regulatory factors, which cause IFN-1, IFN-II, and IFN-III to be generated. 187 IFNs attach to receptors on nearby cells, signaling them to be on the lookout for a viral threat. This IFN receptor engagement activates various members of Janus kinases and the signal transducers and activators of transcriptions (JAK-STAT) signaling pathway families. The JAK-STAT signaling pathway is one of the main regulatory cell signaling cascades for many cytokines and growth factors. 188 The nonreceptor JAK family includes JAK1, JAK2, JAK3, and tyrosine kinase 2 (Tyk2) proteins. The STAT family comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The JAK-STAT signaling cascade regulates cell growth and differentiation, oxidative stress, and immune modulation, among other biological functions ( Figure 12 ). The JAK-STAT signaling pathway has been unraveled in many DNA and RNA viruses. The interaction of HCV protein with JAK1 through its proline-rich motif is necessary for the development of infectious viruses, indicating that JAK1's function in the HCV life cycle is critical. 189 The JAK-STAT signaling pathway is crucial for the HIV replication via the stimulation of IL-2 by T cells activation in T-lymphocytes. Coronavirus utilizes a variety of mechanisms to hamper IFN production and response. 187 For example, SARS-CoV-1 NSP1 and ORF6 are the main factors that utilize multiplication to measure IFN production and response. As a result, the antiviral JAK1-STAT1 signaling pathway response is inhibited while STAT3 is activated in a compensating manner. 190 STAT3 is a receptor for a harmful IL-6 to stimulate TGF-1β, which may show a crucial role in pulmonary fibrosis development observed in COVID-19 patients. 191 Several studies have shown that, in patients with serious COVID-19 infection, the level of cytokines is elevated. 192, 193 These include IL-1, IL-2, L-6, IL-7, IL-10, TNF-α, granulocyte colony-stimulating hormone, interferon-inducible protein-1α, MCP-1, and MIP-1α. Cytokines have crucial roles in ARDS development, leading to multiple organ failure and even death in patients with COVID-19. This suggests that blocking the cytokine storm through the JAK-STAT signaling cascade may be a potential approach to enhance COVID-19 clinical management techniques currently in use. 194−197 Indeed, several clinical trials are underway investigating JAK-STAT signaling pathway inhibitors in patients with COVID-19. Inflammation-related disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis are all treated with JAK inhibitors. Selected examples are ruxolitinib, 198 baricitinib, 199 tofacitinib, 200 fedratinib, 201 oclacitinib, 202 and upatacitinib. 203 The preservation of JAK1-STAT1 function is one of the first considerations in treating SARS-CoV-2 infection ( Figure 13 ). The virus works by delaying an antiviral reaction while hijacking cellular processes for multiplication. If the infection is identified early, however, using IFN-1 to stimulate JAK1 for the antiviral response may be a viable approach. On the other hand, a delay in IFN-1 treatment would fail to suppress the viral infection and induce cytokines, leading to fatal pneumonia. 187 Since the upper respiratory tract is the main site for viral replication, mucosal therapies of IFN-1 were suggested as a way of preventing SARS-CoV-2. Meng et al. found that using IFN-1 nasal drops in combination with thymosin 1, an immune stimulator, prevented symptoms in over 500 high-risk healthcare Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective workers who came into contact with SARS-CoV-2 affected patients with COVID-19 pneumonia. 204 Some studies have suggested that the H2-mediated antiviral effect could reduce the mortality rate of patients with COVID-19. 205 For example, histamine antagonists may promote the STAT1 activation and IFN response. Indeed, the administration of famotidine (Figure 14) , a histamine H2 receptor blocker, was correlated with a 2-fold decrease in clinical worsening leading to intubation or death in COVID-19 patients. However, it did not show any direct antiviral activity in vitro in Vero E6 cells, although computational studies suggested that famotidine could directly bind to the SARS-CoV-2 NSP5. Ivermectin is an antiparasitic and antiviral drug with a wide range of action. It showed antiviral activity against distinct positive-sense single-strand RNA viruses, which include SARS-CoV-2. With an IC 50 of 2.2−2.8 μM, ivermectin ( Figure 14) inhibited SARS-CoV-2 in the cellular study, making it a possible candidate for the COVID-19 drug repurposing approach. 206 Authors claimed that ivermectin blocked the nuclear transport of viral proteins mediated by KPNA/KPNB1. On the other hand, ivermectin inhibits STAT3 and IL-6 production by inhibiting p21 activated kinase (PAK1), an oncogenic serinethreonine kinase. 207 Aberrantly activated STAT3 can also be controlled by regulation of endogenous inhibitor PIAS3. 208 Some inhibitors like curcumin and resveratrol have shown to be promising in suppressing the constitutive activity of STAT3 209 through upregulation of PIAS3. However, they did not show any effect in any randomized, placebo-controlled clinical trials, although both have been widely used for many indications. Tofacitinib (3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile) (Figure 15 ) is an orally available JAK inhibitor that is approved as an anti-inflammatory agent to treat RA, an autoimmune disease. It inhibits JAK3 and TYK2 ( Figure 13 ) with an EC 50 of less than 5 nM, suppressing inflammatory cytokines like IL-2, IL-4, IL-6, and IL-7 that are linked to RA. 210 Tofacitinib has a decent pharmacokinetic profile, with 74% oral bioavailability and a half-life of 2.3−3.1 h. 210 In RA patients, tofacitinib showed a consistent safety profile and efficacy. However, there is a risk of herpes zoster, cellulitis infections, and thrombosis with the use of tofacitinib. 211 This drug was demonstrated to be effective in COVID-19 patients who had a 13-year history of ulcerative colitis. All symptoms were resolved without the need for hospitalization after 2 weeks, according to the recent report. 212 The study suggested that tofacitinib therapy can be continued in patients suffering from SARS-CoV-2, but it was not shown that tofacitinib helped patients recover from COVID-19 in this situation. Several clinical trials have been started to see how it will help with COVID-19 (see, for example, in Table 3) . Another report proposed the selective JAK2 inhibitor fedratinib (N-tert-butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide) (Figures 13 and 15 ) that has been accepted for myelofibrosis as a possible candidate in COVID-19 management to suppress TH17-associated cytokine activation. 213 TH17 type responses are mediated by several cytokines linked to extreme COVID-19 patients, and TH17 cells themselves produce IL-17 and GM-CSF. It was found that murine TH17 cells treated with fedratinib showed decreased expression of IL-17, and therefore, this can be promising to prevent the outcomes of TH17-associated cytokine storm in COVID-19 patients. Ruxolitinib ((3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile) (Figures 13 and 15 ), is an orally available medication that suppresses the elevated levels of cytokine production associated with myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Ruxolitinib was demonstrated to inhibit HIV-1 virus replication in lymphocytes and macrophages 214 by suppressing a range of cytokines like IL-β, IL-2, IL-5, IL-6, IL-7, IL-13, IL-15, and IFNG. 215−217 In peripheral blood mononuclear cells, it inhibits the phosphorylation of STAT3 by IL-6 and the development of monocyte chemoattractant protein-1. 218 In animal studies, oral administration of ruxolitinib was found to be involved in cytokine suppression. The antiviral potency of ruxolitinib also proved to be effective against Epstein−Barr (EBV) infection. 219, 220 Mechanistically, ruxolitinib inhibited the EBV-infected proliferation and reduced cytokines by inhibition of STAT3. 221, 222 Since ruxolitinib is a powerful candidate for the diseases associated with the hyperimmune syndrome, its efficacy has been employed in COVID-19 patients. As a result, when compared to the control group, patients who obtained ruxolitinib plus standard of care had a quicker clinical development and no major side effects. 223 At least 20 clinical trials evaluating the effectiveness of ruxolitinib in patients with COVID-19 are currently underway. Few studies published results revealing its potential to overcome ARD in patients. 224 COVID-19 patients have been reported to be vulnerable to bacterial infections. 225 Since the JAK-STAT pathway mediates signal transduction of type 1 IFNs 226 and is also a player in suppressing virus replication and infection at the early stages, JAK inhibitors in treating COVID-19 patients may have an elevated risk of bacterial infections. 227, 228 Inhibition of the JAK signaling pathway can thus result in suppression of the antiviral responses mediated by type 1 IFNs through the JAK-STAT pathway. Indeed, some experiments demonstrated that patients taking JAK inhibitors have a higher risk of infection. 228, 229 The most frequent side effects identified in patients treated with ruxolitinib 230 and baricitinib, 231 respectively, were urinary tract infections and upper respiratory tract infections. JAK inhibitors have also been linked to an increased risk of viral infections, such as herpes virus reactivation infection. 232 A recent study reported the development of hematologic toxicity in the treatment of ruxolitinib in two patients with COVID-19: one developed soft-tissue infection, and the other one developed an infection associated with herpes labialis. These severe drug reactions led to the suspension of the ruxolitinib treatment in both cases. 233 While type 1 IFNs play an important role in the antibacterial and antiviral responses, their role in coronavirus infections has yet to be fully understood. In animal models of MERS-CoV infection, type 1 IFNs were shown to be useful during the early stages of infection in some trials. However, it was not advantageous in the later stages because it raised the risk of death. 234 Another research study found that IFNα and type II IFN (TFN) signaling were elevated in patients with SARS-CoV-1 infection who experienced hypoxemia and died but lower in those who survived after a comparatively mild SARS illness. 235 The SARS-CoV-2 infection resulted in low IFN expression but substantially improved chemotactic and inflammatory responses, including CCL2, CCL8, IL-6, IL-1 β, and IL1RA, according to a recent review. SARS-CoV-2 infection in patients inhibits IFN-mediated immune cell recruitment and promotion of IFN-stimulated genes. 236 The SARS-CoV-2 entry receptor ACE is also an interferonstimulated gene (ISG) that is primarily expressed in human airway epithelial cells. 237 All of these findings led to the suggestion that further research is needed to classify IFNs in response to SARS-CoV-2 infection, implying that the COVID-19 control strategy targeting JAK inhibition can still be used. It is also possible that selective JAK2 inhibition (e.g., fedratinib) or JAK2 and JAK3 inhibition (e.g., tofacitinib) will be advantageous since they would not interfere with JAK-type 1 IFNmediated antiviral and antibacterial immunity. 238, 239 4.3. The Signaling Pathway of Glycogen Synthase Kinase 3 (GSK-3). Glycogen synthase kinase 3 exists in GSK-3α and GSK-3β isoforms. The kinase domains of the isoforms have a high degree of sequence similarity (98%) between them. 240 It plays a role in metabolism, inflammatory reaction, and modulation of innate immunity. 241 Therefore, targeting GSK-3 has been linked to treating various diseases like diabetes, neurodegenerative disorders, different types of cancer, and bipolar disorders. 242 GSK-3 can mediate the expression of other genes by transcription factors, including c-Jun, CREB, STAT3, C/EBP, NFAT, NF-B, and p53. IL-1, IL-16, 243 IL-17, IL-18, 244 IL-23, 245 IL-12, and IFN-γ, 246 chemokines IL-8, 244 C−C motif chemokine ligands 2, 246 3, 4 and 12, 247 and C-X-C motif chemokine ligands 1, 2, 5, and 10 248 are all positive regulators of GSK-3. In comparison to the MAPK, PI3K, PKC, and Wnt/-catenin signaling pathways, GSK 3 is a lesser-known signaling pathway in the virology field. Recent research suggests that GSK-3 can play a crucial role in viral replication, replication, and pathogenesis. 249, 250 Also, GSK-3 activation is linked to a reduction in host immunity and antioxidant response. The GSK-3-associated signals have been employed in the entry, replication, and egress of various unrelated viruses. 251 GSK-3 has been reported to be involved in the phosphorylation of occludin at Ser341, which enhances the binding and entry of HCV. 252,253 GSK-3β, a substrate for AKT, has been identified as one of the host factors in influenza virus entry. 254, 255 The overexpression of GSK-3β has been associated with HCV entry. 256 In HIV-1 infected T cells and monocytic cell lines, the upregulation of GSK-3β has been identified. 257 Coxsackievirus B3 (CVB3) infection induced GSK-3 expression in HeLa cell lines and a mouse model, resulting in virus-driven cytopathic effects and apoptosis. 258 GSK-3 has been investigated as a possible mediator of HCV virion assembly and release. As a result, blocking GSK-3 259 In HIV-1-infected macrophages or cell lines, inhibiting GSK-3 decreased viral replication, according to another study. 260, 257 In Huh 7.5 cells, inhibition of GSK-3β led to a reduction of both replication and viral particle production of HCV but for hepatitis E virus (HEV). 261 The increased GSK-3β-Ser9 phosphorylation has been linked to the replication of the HBV, 262, 263 indicating a beneficial effect of GSK-3β inhibition for HBV replication. GSK-3 phosphorylation of assembly protein precursor, a protein involved in the organization and maturation of cytomegalovirus, is required. 264, 265 One of the most important structural proteins in coronaviruses, nucleocapsid-protein N, is strongly conserved across organisms. Protein N has a variety of roles in the viral life cycle, the most important of which is packing the virus's genomic RNA into the protective coating. The N protein of SARS-CoV-1 hijacks the host immune system for virus progeny and related diseases to spread. GSK-3 has been linked to SARS-CoV-1 N phosphorylation on a serine residue, which is necessary for viral replication. As a result, it acts as a viral life cycle regulator. 266 The host translational machinery is also inhibited by phosphorylation of N protein, which interferes with antiviral response signaling. Inhibition of GSK 3 in cells infected with SARS-CoV-1 resulted in the prevention of SARS-CoV-1 N phosphorylation, and, as a result, the viral replication was impaired. 66−268 The GSK-3 selective inhibitors LiCl and kenpaullone (9bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6 (5H)-one) ( Figure 16 ) reduced viral titer and cytopathic effects in Vero E6 cells infected with SARS-CoV-1 without affecting cell viability. 266 According to this study, this kinase's phosphorylation is closely linked to viral replication. The nitro analogue alsterpaullone potently inhibits the replication of HIV-1 with an IC 50 value of 150 nM in virus-infected cells. 137 Lithium, a GSK-3 inhibitor, has been used to treat mood and bipolar conditions in patients. In porcine cells, lithium chloride therapy helped to cure a transmissible gastroenteritis coronavirus infection. In avian cells, lithium chloride treatment protects against the bronchitis virus by blocking the synthesis of genomic and subgenomic RNA while leaving the host translation pathways unaffected. A recent study showed the potential antiviral activity of thiadiazolidinone tideglusib ( Figure 16 ) against SARS-CoV-2 M pro activity. 269 Tideglusib (NP031112, NP-12) is a non-ATPcompetitive, irreversible GSK-3 inhibitor that has recently been shown to have an IC 50 of 1.5 μM in inhibiting SARS-CoV-2 M pro . 269 The SARS-CoV-1 N protein has a high degree of resemblance to the SARS-CoV-2 N protein, and both proteins have conserved serine residues (Ser189 and Ser207), according to the sequence analysis. 38 Thus, the serine residues in SARS-CoV-2 are predicted to be phosphorylated by GSK-3 in the same way as they are in SARS-CoV-1. CoV's key protease, which is necessary for viral replication and transcription, is also inhibited by GSK-3 inhibition. 270−272 T cell proliferation and activity are believed to be negatively regulated by GSK-3. 273, 274 Indeed, inhibiting GSK-3 with molecules like SB415286 improved the adaptive CD8+ cytolytic cell (CTL) role significantly. 275, 276 This effect is essential for the production of cytolytic effectors such as granzyme B, perforin, and interferon-γ in CD8+ cells. 277, 278 GSK-3 has an impact on CD4+ T cells, which are essential for the growth of cytokine release syndrome (CRS) in the more extreme COVID-19 cases. Inhibiting GSK-3 with small molecules has been shown to cause CD4+ T cells to produce the suppressive cytokine IL-10, which can help to reduce CRS in severe disease. 279 In infections 280 In addition, inhibiting GSK-3 stimulates the development of natural killer cells, 281 which are innate immune system effector cells that help to control infection. 282 Based on the findings, inhibiting GSK-3 may be a promising therapeutic strategy for preventing SARS-CoV-2 infection by reducing viral replication and enhancing the immune response to the virus, as seen in Figure 17 . The novel human SARS-CoV-2 is a causative agent for COVID-19 that has emerged in the human population. For the treatment of COVID-19, several antiviral agents are being tested in clinical trials as single agents or conjunction with other therapies. Many inhibitors targeting kinases have direct antiviral effects, targeting essential virus-associated proteins and proteins that play a role in the production of COVID-19 symptoms such as pneumonia-like infection, ARDS, cytokine storm, systemic inflammation, and fibrosis. The summary of kinase inhibitors, their original use, and their repurposing for viral diseases, including COVID-19, are outlined in Table 4 . Several of these kinase inhibitors are already approved, and some are being clinically investigated in Phase I− III trials for various diseases. However, adverse effects and pharmacokinetic properties of kinases inhibitors need to be considered, when repurposing them for the treatment of COVID-19. For example, some drugs need long-term dosing to achieve the required pharmacological concentrations and exert their effect, which may not be a suitable option to treat the symptoms associated with COVID-19 as immediate treatment is required for the affected patients. Likewise, treatment of kinase inhibitors associated with a series of side effects or that could decrease immune responses at the beginning of the viral life cycle (e.g., inhibitors that interrupt type 1 IFNs-JAK1, see section 4.2) would pose a challenge for patients infected with COVID- 19 . In a murine model of the vaccinia virus, imatinib, an inhibitor of Abl tyrosine kinase, effectively decreased viral load, dissemination, and mortality. However, it did not protect the mice from the infection. 45 This raises the issue concerning its efficacy in governing the viral infection in vivo. In animal models of other viral infections, such as SARS-CoV-2, it is crucial to investigate the antiviral efficacy and safety profile of drugs that target Abl and Src. Combination therapy in the context of COVID-19 will have significant therapeutic advantages, as this technique has previously been seen to be effective in the treatment of lifethreatening diseases including HIV-related AIDS. As a result, antivirals (ribavirin, ritonavir-lopinavir, remdesivir) combined with kinase inhibitors (sunitinib, erlotinib, sorafenib, imatinib, gilteritinib, gilteritinib, osimertinib) or kinase inhibitors that target both virus-related proteins and proteins associated with pulmonary health would be beneficial. One of the effective therapeutic techniques in the control of the COVID-19 pandemic may be to target the JAK-STAT signaling pathway. This signaling pathway mediates a hyperimmune activation by proinflammatory cytokines that leads to ARD, organ damage, and ultimately death in COVID-19 patients. Therefore, the approach that allows the repurposing of already FDA-approved and experimental drugs targeting the . GSK-3 as a possible target for anti-coronaviral treatment, such as anti-SARS-CoV-2 therapy. According to the model, inhibiting GSK-3 will also inhibit SARS-CoV-2 N protein and improve CD8+ T cell resistance to the virus. Left: SARS-CoV-2 N protein and viral replication are assumed to be inhibited by inhibiting GSK-3. Right: Inhibition of GSK 3 improves CD8+ cell responses to viruses. In CD8+ T cells, inhibiting GSK-3 decreases the expression of inhibitory receptors PD-1 and LAG-3 while increasing the expression of GMZB and IFNg1. Inhibition of GSK-3 also escalates natural killer function. PD-1, programmed cell death protein 1; LAG-3, lymphocyte-activation gene 3; GMZB, granzyme B; IFNg1, interferon-gamma. Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective JAK-STAT signaling pathway would be potentially beneficial. Additionally, drugs that selectively target JAK2, JAK3, or JAK2/ 3 would be a potential treatment option concerning the suppression of cytokines, and at the same time, they would not interrupt IFN-JAK1-mediated antiviral and antibacterial immunity in patients infected with COVID-19 ( Figure 13 ). On the other hand, bacterial infections can be a risk factor for using JAK-STAT pathway inhibitors for COVID-19 because JAK inhibitors inhibit IFN type 1 IFNs, which are formed in response to bacterial infections, and thus can prevent viral replication and infection. 227, 228 However, selective inhibitors that target JAK2/ JAK3 can still be repositioned for COVID-19 treatment as they would not interact with JAK-1. ) WHO Coronavirus (COVID-19) Dashboard; World Health Organization COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 The recent outbreaks of human coronaviruses: A medicinal chemistry perspective Recent discovery and development of inhibitors targeting coronaviruses The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status SARS and other coronaviruses as causes of pneumonia An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy Summary of probable SARS cases with onset of illness from 1 Middle East respiratory syndrome-coronavirus (MERS-CoV): An updated overview and pharmacotherapeutics Genomic characterisation and epidemiology of Exploiting existing molecular scaffolds for long-term COVID treatment Candidate drugs against SARS-CoV-2 and COVID-19 Severe covid-19 pneumonia: Pathogenesis and clinical management Coronavirus infections and immune responses Clinical features of patients infected with 2019 novel coronavirus in Wuhan The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Human immunopathogenesis of severe acute respiratory syndrome (SARS) The mercurial nature of neutrophils: Still an enigma in ARDS? Pathological findings of COVID-19 associated with acute respiratory distress syndrome Repurposing of kinase inhibitors for treatment of COVID-19 Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells Interactions between calmodulin and neurogranin govern the dynamics of CaMKII as a leaky integrator The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases Dasatinib: A new step in molecular target therapy Regulation of cell migration and morphogenesis by Abl-family kinases: Emerging mechanisms and physiological contexts Antiviral potential of ERK/ MAPK and PI3K/AKT/ mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43 Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2. Front. Oncol. 2020, 10, 1428. (47) Bachstetter, A. D.; Van Eldik, L. J. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS p38 Pathway kinases as anti-inflammatory drug targets Recent developments in the use of kinase inhibitors for management of viral Infections Influenzavirusinduced signaling cascades: Targets for antiviral therapy? Development of cellular signaling pathway inhibitors as new antivirals against influenza Influenza virus infections and cellular kinases Repurposing of kinase inhibitors as broadspectrum antiviral drugs Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase Identification of 53 compounds that block Ebola viruslike particle entry via a repurposing screen of approved drugs Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection Hehlmann, R. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Leukemia Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia ABL tyrosine kinases: Evolution of function, regulation, and specificity The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Imatinib is not a potent anti-SARS-CoV-2 drug Targeting nonmalignant disorders with tyrosine kinase inhibitors Imatinib: The narrow line between immune tolerance and activation Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19. bioRxiv Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2 Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis Viral proteins and Src family kinases: Mechanisms of pathogenicity from a 'liaison dangereuse c-Src protein kinase inhibitors block assembly and maturation of dengue virus Identification and characterization of the role of c-terminal Src kinase in dengue virus replication The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening The Src family kinase cyes is required for maturation of West Nile virus particles Identification of an adaptorassociated kinase, AAK1, as a regulator of clathrin-mediated endocytosis Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly Ebolavirus classification based on natural vectors Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects COVID-19) Update: FDA authorizes drug combination for treatment of COVID-19 Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19 A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 broblasts The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases Stimulation of sky receptor tyrosine kinase by the product of growth arrestspecic gene 6 Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinase Giving AXL the axe: Targeting AXL in human malignancy Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells Tyro3 familymediated cell entry of Ebola and Marburg viruses AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells Preclinical studies of gilteritinib, a nextgeneration FLT3 inhibitor Signalling mechanisms and therapeutic opportunities Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCδ Rhinovirusinduced major airway mucin production involves a novel TLR3-EGFR-dependent pathway The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon l and antiviral defense in airway epithelium Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication Plaque assay for human coronavirus NL63 using human colon carcinoma cells Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus European organization for research and treatment of cancer early clinical studies group Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: Is it useful the application in clinical practice? A pilot study First-in human, Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-inclass dual MEK/RAF inhibitor in patients with solid tumors First-in-human Phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies The PRIDE database and related tools and resources in 2019: Improving support for quantification data First-in-human Phase I study of pictilisib (GDC-0941), a potent panclass I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis Overactive EGFR signaling leads to increased fibrosis after SARS-CoV infection The TORrid affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication West Nile virus induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs Novel, selective CDK9 inhibitors for the treatment of HIV infection Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells Role of CDK9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1 Molecular basis for viral selective replication in cancer cells: Activation of CDK2 by adenovirus-induced cyclin E The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication Inhibition of human immunodeficiency virus type-1 by cdk inhibitors Flavopiridol inhibits P-TEFb and blocks HIV-1 replication Repurposing kinase inhibitors as antiviral agents to control influenza A Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1 Cell cycle perturbations induced by infection with the coronavirus infectious bronchitis virus and their effect on virus replication Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53 Using or abusing: Viruses and the cellular DNA damage response The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication Viral manipulation of DNA repair and cell cycle checkpoints The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection Arbidol and other low-molecular-weight drugs that inhibit lassa and Ebola viruses Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations CDK4/6 inhibitors expand the therapeutic options in breast cancer: Palbociclib, Ribociclib and Abemaciclib Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib One-thousand-and-one substrates of protein kinase CK2? Phosphorylation events during viral infections provide potential therapeutic targets Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular health Casein kinase 2 regulates vaccinia virus actin tail formation Treatment with an anti-ck2 synthetic peptide improves clinical response in COVID-19 patients with pneumonia. A randomized and controlled clinical trial Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related Disease (COVID-19) Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580 The effect of P38 MAP kinase inhibition in a mouse model of influenza The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis Clinical predictors of mortality due to COID-19 based on an analysis of data of 150 patients from Wuhan, China Modulation of mitogen-activated protein kinase attenuates sepsisinduced acute lung injury in acute respiratory distress syndrome rats Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion Activation and signaling of the p38 MAP kinase pathway Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury N. p38 Mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury Immunologic effects of the renin-angiotensin system angiotensin-(1−7) and Mas receptor axis in inflammation and fibrosis Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor α-converting enzyme (TACE/ADAM-17) activation in primary human monocytes Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Antiviral activity of ginsenoside Rg3 isomers against gamma herpes virus through inhibition of p38-and JNK-associated pathways BerGenBio's bemcentinib selected to be fast-tracked as potential treatment for covid-19 through new national UK government clinical trial initiative; Cision Antiviral screening of multiple compounds against Ebola virus Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses Dimesylate), in patients with advanced cancer Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling Palese, P. 7a Protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal regulated kinase 1/2 signaling Angiotensin-II mediates ACE2 internalization and degradation through an angiotensin-II type I receptor-dependent mechanism Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/ p38 MAP kinase pathway capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19 Mechanisms of Jak/STAT signaling in immunity and disease Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses An aberrant STAT pathway is central to COVID-19 Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19 Immunomodulation in COVID-19 JAK inhibition as a new treatment strategy for patients with COVID-19 Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients The first FDA approved therapy for the treatment of myelofibrosis FDA approves Eli Lilly's Baricitinib FDA approves Tofacitinib for rheumatoid arthritis Fedratinib becomes new option in myelofibrosis JAK inhibitors in dermatology: The promise of a new drug class Upadacitinib: First approval An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area Histamine receptors and COVID-19 The FDA-approved drug ivermectin inhibits the replication of SARSCoV-2 in vitro Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer Specific inhibition of STAT3 signal transduction by PIAS3 Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study Incidence of venous and arterial thromboembolic events reported in the Tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on Tofacitinib TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors IL-15 regulates susceptibility of CD4+ T cells to HIV infection Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo Inflammation research association-15th international conference advances in asthma and COPD and other inflammatory diseases Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target Longterm survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study The yin and yang of type I interferon activity in bacterial infection Decoding type I and III interferon signalling during viral infection The host type I interferon response to viral and bacterial infections Ruxolitinib-associated infections: A systematic review and metaanalysis Systematic review and meta-analysis of serious infections with Tofacitinib and biologic disease modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials Response to Ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Side effects of Ruxolitinib in patients with SARS-CoV-2 infection: Two case reports IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes Canadian SARS research network. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases GSK3 and its interactions with the I3K/AKT/mTOR signalling network Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging Glycogen synthase kinase 3: An emerging therapeutic target Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging Glycogen synthase kinase-3β inhibitor reduces LPS induced acute lung injury in mice IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3β Stressed and inflamed, can GSK3 be blamed? A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2 TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression Glycogen synthase kinase-3β promotes liver innate immune activation by restraining AMPactivated protein kinase activation Fine-tuning of the RIG-Ilike receptor/interferon regulatory factor 3-dependent antiviral innate immune response by the glycogen synthase kinase 3/ beta-catenin pathway GSK-3-associated signaling is crucial to virus infection of cells A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro Computational identification of interplay between phosphorylation and O-beta-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry Emerging cellular targets for influenza antiviral agents Inhibition of Akt kinase activity suppresses entry and replication of influenza virus Glycogen synthase kinase-3β enhances hepatitis C virus replication by supporting miR-122 Novel neuroprotective GSK-3β inhibitor restricts tat-mediated HIV-1 replication Inhibition of glycogen synthase kinase-3β suppresses coxsackievirusinduced cytopathic effect and apoptosis via stabilization of beta-catenin Glycogen synthase kinase-3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK-3β inhibitors Glycogen synthase kinase-3β enhances hepatitis C virus replication by supporting miR-122 Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT/GSK-3beta/beta-catenin signaling pathway Assembly of herpes simplex virus type 1 capsids using a Journal of Medicinal Chemistry pubs Assembly protein precursor (pUL80.5 homolog) of simian cytomegalovirus is phosphorylated at a glycogen synthase kinase 3 site and its downstream "priming" site: Phosphorylation affects interactions of protein with itself and with major capsid protein Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors Commentary: GSK-3 Inhibition as a therapeutic approach against SARs CoV-2: Dual benefit of inhibiting viral replication while potentiating the immune response The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Glycogen synthase kinase 3: A kinase for all pathways? Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3 Two strings in one bow: PD-1 negatively regulates via co-receptor CD28 on T cells Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-cells: Implications for anti-PD-1 immunotherapy Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor I immunity Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter The regulation of IL-10 production by immune cells GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity NK cells in host responses to viral infections